Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing and delivering cell and gene therapies for serious diseases with high unmet need. Its ZEVASKYN (prademagene zamikeracel) was approved in April of 2025, and the company operates a fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio that serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio includes PSMA-SIR-T (ABO-701), a potentially first-in-class engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA).

Abeona Therapeutics Inc. is described on its official website as a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Its ZEVASKYN (prademagene zamikeracel) was approved in April of 2025. The company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Vishwas Seshadri joined Abeona as Head of Research & Clinical Development in June 2021 and was appointed President and Chief Executive Officer, and member of the Company's Board of Directors, in October 2021.

• ZEVASKYN (prademagene zamikeracel)

  Approved in April of 2025; manufactured at the company's cGMP facility in Cleveland, Ohio.

• PSMA-SIR-T (ABO-701)

  A potentially first-in-class engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA), being developed for advanced prostate cancer.

1. 1Abeona Therapeutics | Developing Cell and Gene Therapiesabeonatherapeutics.com
2. 2About Abeona Therapeutics Inc. (ABEO)abeonatherapeutics.com
3. 3Our Leadership Team | Abeona Therapeuticsabeonatherapeutics.com
4. 4Pipeline & Science | Abeona Therapeuticsabeonatherapeutics.com
5. 5Abeona Therapeuticswikidata.org